Drucker Wealth 3.0 LLC Has $1.81 Million Stock Position in Medtronic PLC $MDT

Drucker Wealth 3.0 LLC cut its holdings in shares of Medtronic PLC (NYSE:MDT) by 35.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,984 shares of the medical technology company’s stock after selling 10,378 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Medtronic were worth $1,808,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of MDT. Brighton Jones LLC boosted its stake in Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Medtronic in the 2nd quarter worth $10,286,000. Chicago Partners Investment Group LLC boosted its position in shares of Medtronic by 17.6% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 8,194 shares of the medical technology company’s stock worth $754,000 after purchasing an additional 1,224 shares during the last quarter. Finally, Lyell Wealth Management LP acquired a new stake in shares of Medtronic during the second quarter worth $893,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 3.2%

Shares of MDT stock opened at $96.33 on Wednesday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a fifty day moving average of $99.19 and a 200-day moving average of $96.58. The company has a market capitalization of $123.50 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Needham & Company LLC upgraded shares of Medtronic from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a research report on Monday, February 9th. CICC Research assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. Royal Bank Of Canada upped their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Finally, Wells Fargo & Company started coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $111.21.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic exceeded consensus on revenue (~$9.02B) and adjusted EPS ($1.36), driven by robust demand for heart devices and diabetes monitors, supporting the bullish growth story. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Strong segment performance — Cardiovascular (including cardiac ablation/PFA) and Diabetes delivered outsized growth (cardiac ablation growth cited very strong), making this one of the company’s best quarters in recent years and underpinning revenue momentum. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Positive Sentiment: Regulatory/product wins — FDA clearance and immediate commercial activity for the Hugo™ robotic system (first U.S. case performed) and clearances for other surgical/spine systems expand addressable markets and could accelerate procedure volumes. Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic
• Positive Sentiment: Additional approvals and pipeline progress — FDA nod for Infuse bone graft in TLIF procedures and MiniMed Flex submission keep product catalysts on the calendar for surgical and diabetes franchises. Medtronic gets FDA nod for Infuse bone graft in TLIF procedures
• Neutral Sentiment: Guidance reiterated — Management reaffirmed FY26 organic revenue and EPS guidance (EPS range ~5.620–5.660), which was neither a downside shock nor a strong upside catalyst; investors are parsing precision of margins and timing of improvement. Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth
• Neutral Sentiment: Technicals/analyst outlook — Technical analysts and MarketBeat highlight a “textbook” reversal and institutional accumulation that imply upside targets in the $118–$125 range; this is supportive longer term but doesn’t offset near‑term margin concerns. Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?
• Negative Sentiment: Margin pressures and costs — Investors reacted to margin contraction (tariffs, higher costs, and investments) and reports that GAAP profit fell despite higher revenue; these near‑term profitability headwinds help explain the stock decline. Medtronic Profit Falls Despite Higher Revenue

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).